Bud and Yvonne are delighted by Bud's recovery thanks to Gleevec
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
Brian Druker talks about how Gleevec has restored patients' hope for the future.
Brian Druker credits the drug company Novartis with recognizing the importance of Gleevec and accelerating the development and approval process.
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
View the animation to learn about the Philadelphia chromosome, the abnormal chromosome that causes chronic myeloid leukemia.
Yvonne, Bud's wife, talks about the first day of the clinical trials in June of 1998.
Brian Druker talks about sense of urgency.
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.